Stereotaxis (STXS) Q4 2025 earnings review
Regulatory Wins Eclipsed by Manufacturing Bottlenecks
Stereotaxis finally secured its long-awaited FDA and European approvals for the GenesisX robot and MAGiC catheter portfolio. Total Q4 revenue grew 36% YoY to $8.6M. However, the operational execution is lagging the regulatory wins. Management admitted to manufacturing challenges that severely stunted the commercial rollout. Most alarmingly, the critical 'Recurring Revenue' segment actually reversed its sequential trend, dropping to $5.28M in Q4 and vastly missing the company's prior $7.0M guidance for the quarter. While FY26 guidance projects revenue accelerating past $40M, a depleted backlog and a razor-thin cash balance of $13.4M leave zero margin for error in the upcoming commercial ramp.
🐂 Bull Case
The company successfully navigated the FDA and European regulatory hurdles for its core future portfolio: GenesisX robot, MAGiC ablation catheter, and MAGiC Sweep mapping catheter. The foundational technology is legally clear to sell in major markets.
FY26 guidance of >$40 million implies >23% YoY growth, accelerating from FY25's 20%. The addition of the Synchrony Digital Surgery Suite is expected to contribute $3M+ in new revenue.
🐻 Bear Case
Despite heavily promoting a shift to a 'razor/razorblade' model, Q4 recurring revenue of $5.3M missed earlier $7M targets and sequentially declined from Q2 and Q3 levels. The promised catheter adoption is not yet materializing in the numbers.
Management explicitly cited 'challenges in ramping manufacturing of MAGiC and GenesisX' as the reason for modest commercial contributions. Scaling hardware production is notoriously difficult and capital-intensive.
⚖️ Verdict: 🔴
Bearish. While regulatory approvals validate the R&D, the failure to hit the Q4 recurring revenue target by over 24% ($5.3M actual vs $7M guide) due to supply chain/manufacturing issues is a glaring red flag. Execution risk is now extremely high.
Key Themes
Manufacturing Struggles Choke Catheter Rollout
The entire bullish thesis for STXS relies on the high-margin, proprietary MAGiC catheter portfolio driving recurring revenue. In earlier 2025 calls, management guided for $7M in Q4 recurring revenue. The actual print was $5.28M—a sequential deceleration from Q3 ($5.60M) and Q2 ($5.76M). Management blamed this directly on 'challenges in ramping manufacturing.' If they cannot physically produce the disposable catheters at scale, the newly approved GenesisX robots will lose their recurring revenue leverage.
System Backlog Depletion
System backlog at the start of 2026 sits at $9.1 million. This is a severe deterioration from the $15.2 million backlog reported at the start of 2025. While Q4 saw system revenue jump to $3.36M (partial recognition on two Genesis robots), the pipeline is shrinking. The company needs GenesisX orders to rapidly outpace legacy Genesis orders to replenish this backlog and hit 2026 targets.
GenesisX Robot Enters Commercial Phase
The GenesisX system is meant to remove the massive structural and hospital construction barriers that plagued the legacy Genesis system. With approvals in hand, management's FY26 goal is to establish 'at least five active GenesisX programs.' This is the primary driver for stabilizing and growing capital equipment sales, which grew 18% in FY25 to $10.2M.
Synchrony Digital Suite Introduces New Business Pillar
Management laid down a firm FY26 target for its Synchrony Digital Surgery Suite: receive FDA approval, deliver over $3 million in revenue, and integrate early AI features. This represents a completely new product line outside of the traditional capital/disposable hardware mix, acting as an incremental growth driver.
Cash Runway Leaves Zero Room for Error
Stereotaxis ended FY25 with $13.4 million in cash and no debt, having tapped an ATM offering in Q4 for $3.1 million. Adjusted operating losses were $9.3M for the full year. While management expects 'reduced cash use in 2026' and positive cash flow from working capital, any further manufacturing delays or slower-than-expected commercial adoption will force the company back to the equity markets, risking severe shareholder dilution.
Other KPIs
Stable compared to 54% in FY24. Recurring gross margins were 67%, compressed by acquisition-related accounting from the APT deal and lower initial margins on newly launched devices. System gross margins were a dismal 21%, heavily pressured by fixed overhead spread across very low production volumes.
Reversing/Decreasing from $7.2 million in 24Q4. The company recognized $3.0M in non-cash charges in Q4 (stock comp, earnout mark-to-market). Maintaining flat-to-down adjusted OpEx is critical given the current cash burn trajectory.
Guidance
Accelerating. Implies YoY growth of at least 23.5% over FY25's $32.4 million. Management expects both system and recurring revenue to increase throughout the year in line with manufacturing ramps.
New metric. Accelerating from zero base, contingent on receiving FDA approval and commercializing the digital solution for the endovascular surgical suite.
Accelerating production run-rate target for year-end 2026, highlighting the specific volume needed to support the projected recurring revenue growth and resolve the current supply bottlenecks.
Key Questions
Recurring Revenue Miss
In earlier 2025 calls, you guided to $7 million in Q4 recurring revenue, yet the print was $5.3 million—a sequential decline. How much of this gap was strictly manufacturing supply versus slower hospital adoption curves?
Manufacturing Bottlenecks
You cited challenges in ramping manufacturing for MAGiC and GenesisX. What exactly are the specific constraints (raw materials, yield, labor), and why will it take until year-end 2026 to reach the 500-unit monthly target for MAGiC?
Cash Runway and Working Capital
You expect positive cash flow from working capital in 2026 after a $5.6M investment in 2025. Given the $13.4M cash balance, what is the minimum quarterly revenue run-rate required to achieve cash-flow breakeven before needing to raise additional capital?
System Backlog Visibility
The system backlog declined from $15.2M at the start of 2025 to $9.1M today. What is the current pipeline velocity for the GenesisX, and how quickly do you expect to rebuild the backlog now that approvals are secured?